Dr. Andreas Briel is founder and CTO of iDEL Therapeutics GmbH as well as main inventor of iDEL's cytosolic drug delivery technology. He has a profound track record as MedTec and Pharma entrepreneur - e.g. founder and owner of nanoPET Pharma GmbH operating since 2008, and XIRALITE GmbH founded in 2017. With the focus on Diagnostic Imaging and Drug Delivery Technologies he managed the development of more than 36 products within 18 years from the invention to international marketing (www.viscover-online.de).
Prior to his C-level management dedication, Andreas was involved in Bayer´s Corporate Research Business Area “Diagnostic Imaging” and has successfully established an own research team dealing with special research topics on nanomedicines. He initiated and implemented several new business opportunities linking Imaging Device Manufacturers like Siemens Healthineers AG and Philips Medical Systems B.V. with Bayer-Schering as a Pharma-Player. Additionally, he has been involved in several initiatives to consult the German government and the European Commission as well as the European Science Foundation.
Initially, Andreas joined Schering AG in Berlin in 1996 and worked 3 years on the pharmaceutical development of Imaging Agents (CMC supporting Phase I & II clinical trials, and international project team leader for novel contrast agents), 2 years in the Drug Delivery Systems Department and 2 years in the CMC-Technology Office of Schering evaluating recent developments in drug delivery technologies.
Andreas studied chemistry at Philipps-Universität in Marburg (Germany) with the focus on physical-chemistry of polymers and has subsequently developed research interest in the field of structure control of macromolecules with different nano-architectures unleashing novel and unique features. He completed his PhD studies in 1996 at the Max-Planck-Institute of Colloids and Interfaces.
